2020
06/02/2020 Enteris BioPharma to Participate in BIO International Digital Convention05/04/2020 Enteris BioPharma Appoints Rajiv Khosla, Ph.D., as Chief Executive Officer
02/10/2020 Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
01/27/2020 Enteris BioPharma Awarded 2019 Best of Boonton Prize
01/06/2020 Enteris BioPharma Highlights 2019 Achievements and 2020 Outlook
2019
12/06/2019 KORSUVA™ Top Line Data Phase 2 CKD08/27/2019 SWK Holdings Corporation Acquires Enteris BioPharma
08/21/2019 New Licensing Agreement for Oral KORSUVA™ with Peptelligence®
07/11/2019 Oral KORSUVA™ in Phase 2 for Atopic Dermatitis
06/27/2019 Oral KORSUVA™ in Phase 2 Trial for Pruritus Treatment
06/02/2019 Ovarest®, Tobrate® at New Rhein Industry Day
03/05/2019 Enteris BioPharma Supports Endometriosis Awareness Month
2018
12/18/2018 Enteris BioPharma to Present at Biotech Showcase 201907/19/2018 First Patient Dosed in Trial of Oral KORSUVA™
06/26/2018 Positive Results in Ovarest® Endometriosis Trial
04/30/2018 Expanded Trial for Endometriosis Initiated
03/15/2018 Enteris President & CFO to Present at Future Leaders
03/05/2018 Ferring Continues Peptide Development With Enteris
03/01/2018 First Patient Dosed in Phase 1 Trial of Oral (CR845) KORSUVA™
01/03/2018 Positive Results in Ovarest® Clinical Trial for Endometriosis Treatment
2017
10/31/2017 Peptelligence®-Tech and Cara's CR845 Enters Phase 1 Trial09/19/2017 Enteris BioPharma to Present at BioPharm America
08/24/2017 Enteris Doses First Woman In Phase 2a Clinical Trial for Endometriosis
06/13/2017 Enteris BioPharma to Present at BIO 2017
03/30/2017 Enteris to Present at BioCentury's Future Leaders
01/30/2017 Ferring, Enteris to Develop Oral Peptide Therapeutic
01/25/2017 Enteris, KeyBioscience to Develop Solution for Metabolic Disorders
01/23/2017 Enteris, Sanofi to Develop Oral Therapeutic for Type 2 Diabetes
2016
09/19/2016 Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence®-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain07/13/2016 Enteris BioPharma Initiates Clinical Program for Tobrate (oral tobramycin tablet) in Uncomplicated Urinary Tract Infection
01/19/2016 Enteris BioPharma Enhances Executive Leadership Team to Target Strategic Growth Opportunities
2015
10/19/2015 Enteris BioPharma’s Formulation Technology Enables Oral Delivery of Tarsa Therapeutics’ TBRIA™ – the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis7/14/2015 Enteris BioPharma Oral Formulation Progresses Into Phase 2 Study With Cara Therapeutics’ CR845
2/10/2015 Enteris BioPharma Launches Contract Manufacturing within 32,000 Square Foot, FDA inspected and cGMP Compliant Facility
2014
12/09/2014 Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial06/20/2014 Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug
01/09/2014 Enteris BioPharma to Present at Biotech Showcase™ 2014
2013
12/03/2013 Enteris BioPharma Forms Scientific Advisory Board to Enhance Leadership in Oral Delivery of Peptide and Small Molecule Drugs09/30/2013 Enteris BioPharma and Nordic BioScience’s KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris’ Proprietary Oral Drug Delivery and Manufacturing Platform
08/20/2013 Enteris BioPharma Appoints Timothy J. Saxon, Vice President of Business Development, to Expand “Peptelligence® Partnering” Program
08/05/2013 Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
